nVerses Capital’s Lifecore Biomedical LFCR Stock Holding History

nVerses Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,027	Closed	-$37.3K	–	440
2026 Q1	$37.3K	Buy	+10,027	New	+$69.2K	0.03%	344

Other funds holding LFCR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

nVerses Capital's LFCR Position: Q2 2026 in Review

nVerses Capital sold out of Lifecore Biomedical (LFCR) in Q2 2026, closing a stake of 10,027 shares — an estimated $37.3K sold.

nVerses Capital first reported a position in LFCR in Q1 2026 and held it in 1 quarter. The position peaked at $37.3K in Q1 2026. 67 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

nVerses Capital reported no remaining Lifecore Biomedical position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 10,027 Lifecore Biomedical shares in Q2 2026, an estimated $37.3K.
nVerses Capital first reported a position in Lifecore Biomedical in Q1 2026 and held it in 1 quarter.
nVerses Capital's Lifecore Biomedical position peaked at $37.3K in Q1 2026.
67 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.